LeapZipBlog: freemexy's blog: The world’s biggest generic pharmaceutical companies in 2018

The world’s biggest generic pharmaceutical companies in 2018

August 7, 2019 by freemexy  

The world's biggest generic pharmaceutical companies in 2018


Mylan emerged as the world's biggest generic pharmaceutical company in 2018 despite a decline in net sales, as the industry peers face turbulence due to price erosion and pricing regulations. Pharmaceutical-technology.com lists the world's biggest generic drug sellers based on revenues from January to December 2018. Except Teva Pharmaceuticals and Sanofi, none others from the top ten list currently market patented drugs.Raloxifene powder

Sanofi's generics business posted net sales of $1.69bn in 2018, which was a decline of 9.8% compared to the preceding year. The reduction was primarily due to the divestment of the company's European generic business, Zentiva, in the second half of the year. The divestment was aimed at reorienting and streamlining the company's operations.

The company's net sales from generics increased by 3.8% in the emerging markets. The company also witnessed lower sales in the US and European regions, which was offset by higher sales in the rest-of-the-world (ROW) region, especially in Japan.

Sanofi launched a generic powder form of Renvela® in the US market during the year. Renvela® is indicated to control serum phosphorus in patients with chronic kidney disease undergoing dialysis.

Based in France, Sanofi is a pharmaceutical company with business organised under five global units, including general medicines and emerging markets, speciality care, vaccines, consumer healthcare, and diabetes and cardiovascular.The global generics segment of Dr. Reddy's accounted for approximately 80% of the company's revenue in 2018, with North America being the biggest contributor.

As of March 2018, the company filed 20 abbreviated new drug applications (ANDAs) and had 110 generic filings pending for approval with the US FDA. It also launched five first-generic-to-launch (FGTL) products in Brazil.

Based in India, Dr. Reddy's is a pharmaceutical company whose generic formulations business offers more than 200 high-quality generic drugs worldwide with over 20 assets falling under the complex generics category, including decitabine, fondaparinux, and azacitidine injections.

The company's generic formulations segment includes tablets, capsules, injectables, and topical creams. Omez (Omeprazole), Nise (Nimesulide), Stamlo (Amlodipine Besylate), and Razo (Rabeprazole) are some of its products available in the emerging markets.